Year in Review
Year ended March 2024
Key Figures
- Net Sales
- ¥1,105.4billion
- 4.1%
- Operating Income
- ¥84.3billion
- 11.8%
- Operating Income Ratio
- 7.6%
- 0.5percentage points
- ROE
- 6.9%
- 3.1percentage points
- Capital Expenditures
- ¥53.4billion
- R&D Expenses
- ¥34.7billion
Breakdown by Segment
- Food
- Pharmaceuticals
Net Sales
Operating Income
Business Performance Analysis
Food
- Net Sales
- ¥900.1billion
- 4.0%
- Operating Income
- ¥64.3billion
- 15.1%
- Income Analysis(Billions of yen)
-
Pharmaceuticals
- Net Sales
- ¥206.1billion
- 4.5%
- Operating Income
- ¥22.7billion
- 4.6%
- Income Analysis(Billions of yen)
-
Capital Expenditures
- Food
- Pharmaceuticals
Food
¥39.2billion
Pharmaceuticals
¥13.6billion
Cash Dividends per Share / Dividend Payout Ratio
- Cash Dividends per Share
Dividend Payout Ratio
Future Prospects
This is our Medium-term Business Plan,
FYE 3/2023 through FYE 3/2025.
| FYE3/2023 Results |
FYE3/2024 Results |
FYE3/2025 Plan |
||
|---|---|---|---|---|
| Net sales | ¥1,062.1 biliion | ¥1,105.4 biliion | ¥1,159.0 biliion | |
| Operating income | ¥75.4 billion | ¥84.3 billion | ¥86.0 billion | |
| Operating income ratio | 7.1% | 7.6% | 7.4% | |
| ROE | 10.0% | 6.9% | 7.0% | |
| as of May 10, 2024 |